Azenta, Inc. (AZTA) — ESG & Values Scores

Environment story

Azenta's environmental posture is below-average due to material disclosure gaps and lack of verifiable net-zero commitments. The company acknowledges climate-change regulatory risks and has identified physical climate vulnerabilities (sample storage facilities exposed to extreme weather), yet provides no quantified Scope 1, 2, or 3 emissions data in available filings. No explicit net-zero target year is disclosed. The company's risk disclosure focuses on future cost exposure rather than demonstrated mitigation infrastructure. Two Indianapolis facilities are noted as tornado-prone, and the company faces energy-cost volatility from potential carbon pricing, indicating awareness but no operational decarbonization strategy is evident. Gene synthesis operations carry biosafety risks. No verified renewable-energy percentage disclosed. The company acknowledges ESG cost pressures and reputational risk from environmental initiatives, but lacks concrete investments in physical decarbonization or supply-chain carbon reduction.

Criticisms on file

Material Weakness in Internal Controls Related to Cash Flow Reporting
Source: AZTA 10-K, Item 1A Risk Factors; SEC filing September 30, 2025. Multiple immaterial misstatements in Consolidated Statements of Cash Flows across fiscal years 2022–2025 due to inadequate controls.
Undisclosed Emissions and No Verifiable Net-Zero Target
Source: AZTA 10-K Risk Factors. Company explicitly states 'Global climate change and related legal and regulatory developments could negatively affect our business' but provides zero quantified emissions or net-zero year target, indicating incomplete ESG disclosure.
Geopolitical Supply Chain Disruption Risk
Source: AZTA 10-K, Risks Related to Geopolitical Tensions. Company acknowledges reliance on suppliers in China and Asia; BIOSECURE Act and U.S. Department of Justice Bulk Transfer Rule (effective December 27, 2024) restrict cross-border genomic-data transfers and could force supply-chain reconfiguration, creating operational and decarbonization complexity.

Disclosed initiatives

Climate Regulation Risk Awareness

Company acknowledges future environmental regulation could increase energy costs and require facility modifications to reduce carbon emissions.

Prospective only; no quantified reductions demonstrated.
Gene Synthesis Biosafety Protocols

Federal Select Agent Program (FSAP) compliance measures established for biosecurity in synthetic gene operations.

Regulatory compliance mechanism; not a carbon-mitigation initiative.

Social story

Azenta's social audit reveals mixed performance. No material labor controversies, union-suppression activities, or major strikes are documented in the 10-K, supporting a favorable score on labor relations. However, critical diversity and pay-equity disclosures are absent. Executive and leadership diversity percentages are not provided in available filings, preventing direct assessment against the 30% threshold. CEO-to-median-worker pay ratio is undisclosed, blocking calculation of the 200:1 penalty. No supply-chain human-rights audit or cobalt/conflict-minerals mitigation plan is detailed beyond generic Dodd-Frank compliance acknowledgment. The company discloses foreign operations and genomic services in China (39% of FY2025 revenue; expected to grow) but does not address worker protections, living wages, or forced-labor risks in those jurisdictions. High employee retention challenges and remote-work policy tensions are flagged as risks. Overall, absence of proactive diversity metrics, pay-equity reporting, and supply-chain ethics transparency warrants a below-neutral social score despite no active union-suppression evidence.

Criticisms on file

Undisclosed Executive and Leadership Diversity
Source: AZTA 10-K. No EEO-1 disclosure, gender/racial breakdown of leadership, or executive diversity metrics provided in Risk Factors or Business sections.
Undisclosed CEO-to-Median-Worker Pay Ratio
Source: AZTA 10-K. No CEO compensation relative to median employee pay disclosed.
High-Risk Supply Chain in China Without Documented Labor Audits
Source: AZTA 10-K, Item 1A Risk Factors and International Operations. Company acknowledges 39% FY2025 revenue from China, expects growth, but provides no independent labor-standards audits, living-wage commitments, or forced-labor certifications for Chinese operations or suppliers.
Employee Turnover and Remote-Work Policy Friction
Source: AZTA 10-K, Item 1A Risk Factors: 'The continuing service of our executive officers and essential engineering, scientific and management personnel... The same could be true if we were to experience a high turnover rate... Our ability to attract and retain employees may be negatively impacted by employees' reactions to our policies related to working remotely, particularly in the United States.'

Disclosed initiatives

Conflict Minerals Compliance (Dodd-Frank Disclosure)

Company acknowledges disclosure requirements regarding conflict minerals (DRC, adjoining countries) and states customer requests for conflict-mineral-free and hazardous-material-free components.

Compliance-driven; no evidence of independent audits or enhanced supply-chain vetting beyond regulatory minimum.
Key Personnel Retention Focus (Risk Acknowledgment)

Company identifies retention of executive officers and engineering/scientific personnel as a material business risk and acknowledges competition to attract employees.

Risk mitigation only; no proactive retention programs or diversity hiring initiatives detailed.

Governance story

Azenta's governance score reflects significant structural and procedural weaknesses. The company disclosed THREE MATERIAL WEAKNESSES in internal control over financial reporting as of September 30, 2025: (1) inadequate cash-flow-statement review controls (ongoing since FY2024); (2) insufficient account-reconciliation controls (identified Q1 FY2025); and (3) deficient cost-classification controls in the income statement (identified Q3 FY2025). These weaknesses resulted in immaterial but recurring misstatements across multiple fiscal periods (FY2022–FY2025), indicating systemic control deficiencies and management's inability to maintain effective disclosure controls. Remediation timelines are uncertain. No disclosed board independence percentage or share-structure details are available, preventing full assessment. The company faced activist stockholder pressure (Politan Capital Management, Schedule 13D filed September 2023, Cooperation Agreement November 2024); two directors were replaced and three new directors added, creating governance instability. The company acknowledges anti-takeover provisions (Section 203 Delaware DGCL, blank-check preferred stock, forum-selection bylaws) which may entrench management and limit shareholder voice. No lobbying expenditures targeting environmental deregulation are disclosed, suggesting neutral or limited political risk in this area. However, absence of independent verification of board structure, pay equity, and remediation progress compounds governance risk.

Criticisms on file

Material Weakness: Cash Flow Statement Controls (Unresolved Since FY2024)
Source: AZTA 10-K, Item 1A Risk Factors and Management's Assessment of Internal Controls: Inadequate design and maintenance of controls related to cash-flow-statement review resulted in immaterial misstatements in Consolidated Statements of Cash Flows for Q2/Q3 FY2023, full FY2023, Q1/Q2/Q3 FY2024, and Q1 FY2025. Material weakness continues to exist as of September 30, 2025.
Material Weakness: Account Reconciliation Controls (Identified Q1 FY2025)
Source: AZTA 10-K, Item 1A Risk Factors: During Q1 FY2025 (quarter ended March 31, 2025), company identified additional material weakness in controls over preparation and review of account reconciliations. This weakness resulted in immaterial misstatements in condensed consolidated financial statements for interim periods during FY2025 and consolidated financial statements for year ended September 30, 2025. Continues to exist as of September 30, 2025.
Material Weakness: Cost Classification Controls (Identified Q3 FY2025)
Source: AZTA 10-K, Item 1A Risk Factors: During Q3 FY2025 (quarter ended September 30, 2025), company identified third material weakness due to inadequate controls over classification of certain costs between cost of revenue and SG&A/R&D. Resulted in revision of annual financial statements for FY2023 and all interim/annual periods for FY2024 and Q1/Q2/Q3 FY2025. Continues to exist as of September 30, 2025.
Activist Stockholder Engagement and Board Instability
Source: AZTA 10-K, Item 1A Risk Factors and Cooperation Agreement filed with SEC (November 1, 2024). Politan Capital Management LP initiated Schedule 13D (September 14, 2023, as amended); company entered Cooperation Agreement November 1, 2024, expanded Board by 3 directors (Koffey, Cornog, Malus), established Value Creation Committee with 5 members, and agreed two incumbent directors would not seek re-election at 2025 Annual Meeting. Agreement expired October 2, 2025, yet Koffey remains Board member. Company acknowledges 'perceived uncertainties resulting from future actions of Politan... may lead to the perception of a change in the direction of our business, instability or lack of continuity, any of which could negatively impact our stock price and results of operations.'
Anti-Takeover Provisions and Dual-Class Risk (Status Unclear)
Source: AZTA 10-K, Item 1A Risk Factors: Restated certificate of incorporation and bylaws include limitations on written-consent actions, inability to call special meetings, advance-notice requirements, blank-check preferred stock authorization (up to 1,000,000 shares), and Delaware Section 203 business-combination restrictions. Specific dual-class share structure status not disclosed; anti-takeover architecture documented but independence percentage undisclosed.

Disclosed initiatives

Internal Control Remediation Plan (Ongoing)

Management committed to design and implement new processes, procedures, and controls to address cash-flow review, account reconciliation, and cost-classification deficiencies. Remediation expected to continue through fiscal year ended September 30, 2026.

Remediation timeline uncertain; management acknowledges possibility of discovering additional material weaknesses during remediation process.
Activist Stockholder Cooperation Agreement (Politan Capital)

November 1, 2024 Cooperation Agreement expanded Board from prior size, appointed Politan Managing Partner Quentin Koffey and four others to new Value Creation Committee, added Koffey to Human Resources and Compensation Committee, agreed to nominate Committee members at 2025 Annual Meeting, and two incumbent directors stepped down.

Board refreshed but stability/continuity questioned; Cooperation Agreement expired October 2, 2025, yet Koffey remains on Board, creating perceived uncertainty regarding future activist influence.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Azenta, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Azenta, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)